Cited by 463Cancer Genomics and DiagnosticsCancer Cells and MetastasisLung Cancer Diagnosis and Treatment

Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches

Open access
Krebs, Matthew G., Hou, Jian-Mei, Sloane, Robert, Lancashire, Lee, Priest, Lynsey, Nonaka, Daisuke, Ward, Tim H., Backen, Alison +5 more·2012·Journal of Thoracic Oncology

Abstract

Introduction Epithelial circulating tumor cells (CTCs) are detectable in patients with non-small cell lung cancer (NSCLC). However, epithelial to mesenchymal transition, a widely reported prerequisite for metastasis, may lead to an underestimation of CTC number. We compared directly an epithelial marker-dependent (CellSearch) and a marker-independent (isolation by size of epithelial tumor cells [ISET]) technology platform for the ability to identify CTCs. Molecular characteristics of CTCs were also explored.Methods Paired peripheral blood samples were collected from 40 chemonäive, stages IIIA to IV NSCLC patients. CTCs were enumerated by Epithelial Cell Adhesion Molecule-based immunomagnetic capture (CellSearch, Veridex) and by filtration (ISET, RareCell Diagnostics). CTCs isolated by filtration were assessed by immunohistochemistry for epithelial marker expression (cytokeratins, Epithelial Cell Adhesion Molecule, epidermal growth factor receptor) and for proliferation status (Ki67).Results CTCs were detected using ISET in 32 of 40 (80%) patients compared with 9 of 40 (23%) patients using CellSearch. A subpopulation of CTCs isolated by ISET did not express epithelial markers. Circulating tumor microemboli (CTM, clusters of ≥ 3 CTCs) were observed in 43% patients using ISET but were undetectable by CellSearch. Up to 62% of single CTCs were positive for the proliferation marker Ki67, whereas cells within CTM were nonproliferative.Conclusions Both technology platforms detected NSCLC CTCs. ISET detected higher numbers of CTCs including epithelial marker negative tumor cells. ISET also isolated CTM and permitted molecular characterization. Combined with our previous CellSearch data confirming CTC number as an independent prognostic biomarker for NSCLC, we propose that this complementary dual technology approach to CTC analysis allows more complete exploration of CTCs in patients with NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/jto.0b013e31823c5c16

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Hedley BD, Chambers AF. Tumor dormancy and metastasis. Adv Can- cer Res 2009;102:67-101.

Cited by

Sorted by citations

Authors
Krebs, M. G., Hou, J.-M., Sloane, R., Lancashire, L., Priest, L., Nonaka, D., Ward, T. H., Backen, A., Clack, G., Hughes, A., Ranson, M., Blackhall, F. H., & Dive, C.
Affiliations
  • Manchester Academic Health Science Centre (GB)
  • Cancer Research UK Manchester Institute (GB)
  • The Christie NHS Foundation Trust (GB)
  • University of Manchester (GB)
  • AstraZeneca (United Kingdom) (GB)
Corresponding author
Dive, Caroline
Venue
Journal of Thoracic Oncology
Publisher
Elsevier BV
Published
2012-02
Volume
7
Issue
2
Pages
306-315
ISSN
1556-0864 (ISSN-L)
OpenAlex
W2037607269
Cited by
463
References
40
Citations by year
2026: 7 · 2025: 9 · 2024: 22 · 2023: 23 · 2022: 29 · 2021: 45 · 2020: 39 · 2019: 38 · 2018: 40 · 2017: 47 · 2016: 51 · 2015: 34 · 2014: 27 · 2013: 31 · 2012: 18
FWCI
8.48
Type
journal article
Language
en
Open access
Locations
  • Journal of Thoracic Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
Funders
  • AstraZeneca
  • Cancer Research UK (C147/a12328)
  • Academy of Medical Sciences (AMS-SGCL7-Krebs)
  • European Commission
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
circulating tumor cells, non-small cell lung cancer, epithelial-mesenchymal transition, CellSearch, circulating tumor microemboli, epithelial markers, Ki-67 proliferation index, EpCAM, cytokeratin, epidermal growth factor receptor, CTC enumeration, prognostic factors
MeSH terms
Adenocarcinoma, Aged, Adenocarcinoma, Bronchiolo-Alveolar, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Cell Separation, Epithelial Cells, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplastic Cells, Circulating, Prognosis, Prospective Studies, Biomarkers, Tumor, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review